Company intelligence / Profile preview

KeraCure

Chicago, Illinois, United Statesbiopharmguy.com ↗

Ownership: Private
Development stage: Other

Overview

KeraCure developed a cell-based wound healing product called "KeraPac" containing living keratinocytes. Early results from a nationwide trial in diabetic foot ulcer patients showed superior efficacy to existing treatments. The company was nearing FDA approval and first sales around the late 2000s, targeting a significant market for chronic wound care. No recent data on commercial launch or updated trial results is available.

Therapeutic areas: DermatologyEndocrinology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

1 asset

KeraPac

Unknown

Beyond the preview

Go deeper on KeraCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeraCure.

Explore the full profile